A Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Lu AA24493 in Patients With Acute Ischemic Stroke.
Phase of Trial: Phase I/II
Latest Information Update: 02 Mar 2012
At a glance
- Drugs Lu AA 24493 (Primary)
- Indications Stroke
- Focus Biomarker; Therapeutic Use
- 19 Apr 2011 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 25 Feb 2011 Results from this trial are expected in the first half of 2011.
- 22 Nov 2010 Status changed from recruiting to active, no longer recruiting.